rs145722885

Variant summary

Our verdict is Benign. The variant received -16 ACMG points: 0P and 16B. BP4_StrongBP6_Very_StrongBS2

The NM_012301.4(MAGI2):​c.2213G>A​(p.Arg738Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00222 in 1,613,880 control chromosomes in the GnomAD database, including 11 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.0016 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0023 ( 11 hom. )

Consequence

MAGI2
NM_012301.4 missense

Scores

1
5
13

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:6

Conservation

PhyloP100: 2.16

Publications

9 publications found
Variant links:
Genes affected
MAGI2 (HGNC:18957): (membrane associated guanylate kinase, WW and PDZ domain containing 2) The protein encoded by this gene interacts with atrophin-1. Atrophin-1 contains a polyglutamine repeat, expansion of which is responsible for dentatorubral and pallidoluysian atrophy. This encoded protein is characterized by two WW domains, a guanylate kinase-like domain, and multiple PDZ domains. It has structural similarity to the membrane-associated guanylate kinase homologue (MAGUK) family. [provided by RefSeq, Jul 2008]
MAGI2 Gene-Disease associations (from GenCC):
  • nephrotic syndrome 15
    Inheritance: AR Classification: STRONG, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)
  • familial idiopathic steroid-resistant nephrotic syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • genetic developmental and epileptic encephalopathy
    Inheritance: AD Classification: LIMITED Submitted by: G2P
  • epilepsy
    Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -16 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.00938037).
BP6
Variant 7-78194930-C-T is Benign according to our data. Variant chr7-78194930-C-T is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 129559.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS2
High Homozygotes in GnomAdExome4 at 11 AD,AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
MAGI2NM_012301.4 linkc.2213G>A p.Arg738Gln missense_variant Exon 12 of 22 ENST00000354212.9 NP_036433.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
MAGI2ENST00000354212.9 linkc.2213G>A p.Arg738Gln missense_variant Exon 12 of 22 1 NM_012301.4 ENSP00000346151.4

Frequencies

GnomAD3 genomes
AF:
0.00158
AC:
241
AN:
152156
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000748
Gnomad AMI
AF:
0.00110
Gnomad AMR
AF:
0.00151
Gnomad ASJ
AF:
0.00115
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00311
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00316
Gnomad NFE
AF:
0.00237
Gnomad OTH
AF:
0.00239
GnomAD2 exomes
AF:
0.00198
AC:
496
AN:
250932
AF XY:
0.00223
show subpopulations
Gnomad AFR exome
AF:
0.000554
Gnomad AMR exome
AF:
0.000986
Gnomad ASJ exome
AF:
0.00248
Gnomad EAS exome
AF:
0.0000545
Gnomad FIN exome
AF:
0.000139
Gnomad NFE exome
AF:
0.00270
Gnomad OTH exome
AF:
0.00196
GnomAD4 exome
AF:
0.00229
AC:
3344
AN:
1461606
Hom.:
11
Cov.:
30
AF XY:
0.00239
AC XY:
1738
AN XY:
727124
show subpopulations
African (AFR)
AF:
0.000478
AC:
16
AN:
33464
American (AMR)
AF:
0.00101
AC:
45
AN:
44684
Ashkenazi Jewish (ASJ)
AF:
0.00191
AC:
50
AN:
26116
East Asian (EAS)
AF:
0.0000252
AC:
1
AN:
39682
South Asian (SAS)
AF:
0.00409
AC:
353
AN:
86220
European-Finnish (FIN)
AF:
0.000150
AC:
8
AN:
53410
Middle Eastern (MID)
AF:
0.0109
AC:
63
AN:
5766
European-Non Finnish (NFE)
AF:
0.00240
AC:
2663
AN:
1111886
Other (OTH)
AF:
0.00240
AC:
145
AN:
60378
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.483
Heterozygous variant carriers
0
164
328
491
655
819
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
108
216
324
432
540
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00158
AC:
241
AN:
152274
Hom.:
0
Cov.:
32
AF XY:
0.00154
AC XY:
115
AN XY:
74464
show subpopulations
African (AFR)
AF:
0.000746
AC:
31
AN:
41554
American (AMR)
AF:
0.00150
AC:
23
AN:
15288
Ashkenazi Jewish (ASJ)
AF:
0.00115
AC:
4
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5180
South Asian (SAS)
AF:
0.00311
AC:
15
AN:
4826
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10612
Middle Eastern (MID)
AF:
0.00340
AC:
1
AN:
294
European-Non Finnish (NFE)
AF:
0.00237
AC:
161
AN:
68020
Other (OTH)
AF:
0.00236
AC:
5
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.497
Heterozygous variant carriers
0
11
22
32
43
54
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00212
Hom.:
4
Bravo
AF:
0.00174
TwinsUK
AF:
0.00297
AC:
11
ALSPAC
AF:
0.00415
AC:
16
ESP6500AA
AF:
0.000227
AC:
1
ESP6500EA
AF:
0.00186
AC:
16
ExAC
AF:
0.00204
AC:
248
Asia WGS
AF:
0.000289
AC:
1
AN:
3478
EpiCase
AF:
0.00317
EpiControl
AF:
0.00291

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:3
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Dec 16, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Apr 01, 2023
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

MAGI2: BS2 -

not specified Benign:2
Aug 21, 2015
Eurofins Ntd Llc (ga)
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Aug 01, 2013
Genetic Services Laboratory, University of Chicago
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

MAGI2-related disorder Benign:1
Apr 29, 2021
PreventionGenetics, part of Exact Sciences
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.15
BayesDel_addAF
Benign
-0.48
T
BayesDel_noAF
Benign
-0.46
CADD
Pathogenic
28
DANN
Pathogenic
1.0
DEOGEN2
Benign
0.065
T;T;.;.;.;.;T;.;.;.;T;.
Eigen
Uncertain
0.40
Eigen_PC
Uncertain
0.49
FATHMM_MKL
Uncertain
0.86
D
LIST_S2
Uncertain
0.94
D;D;D;D;D;D;D;D;D;D;D;D
M_CAP
Benign
0.0054
T
MetaRNN
Benign
0.0094
T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Benign
-1.2
T
MutationAssessor
Benign
1.7
.;L;L;.;.;.;.;.;.;.;.;.
PhyloP100
2.2
PrimateAI
Uncertain
0.65
T
PROVEAN
Benign
-0.93
.;N;N;.;.;.;.;N;.;.;.;.
REVEL
Benign
0.077
Sift
Benign
0.043
.;D;T;.;.;.;.;T;.;.;.;.
Sift4G
Benign
0.24
T;T;T;T;T;.;T;T;.;T;.;.
Polyphen
0.96, 0.98, 0.91
.;D;D;.;.;.;.;P;.;.;.;.
Vest4
0.46, 0.41, 0.47, 0.56, 0.53, 0.50
MVP
0.14
MPC
0.36
ClinPred
0.017
T
GERP RS
5.8
PromoterAI
-0.035
Neutral
Varity_R
0.13
gMVP
0.33
Mutation Taster
=100/0
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs145722885; hg19: chr7-77824247; COSMIC: COSV62641915; API